Lisata Therapeutics, Inc. (NASDAQ:LSTA) Sees Significant Decline in Short Interest

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the recipient of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 20,600 shares, a decline of 16.9% from the January 15th total of 24,800 shares. Approximately 0.3% of the shares of the stock are short sold. Based on an average daily volume of 41,200 shares, the days-to-cover ratio is presently 0.5 days.

Hedge Funds Weigh In On Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP lifted its position in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 45.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,226 shares of the company’s stock after acquiring an additional 7,886 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.30% of Lisata Therapeutics worth $75,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.94% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Lisata Therapeutics in a research report on Wednesday, December 11th.

Lisata Therapeutics Stock Performance

Shares of LSTA opened at $2.51 on Monday. The stock has a fifty day moving average price of $2.99 and a two-hundred day moving average price of $2.95. Lisata Therapeutics has a 52-week low of $2.19 and a 52-week high of $4.20. The company has a market cap of $21.06 million, a price-to-earnings ratio of -1.00 and a beta of 1.14.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.